Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
September 13 2024 - 5:45AM
Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the
“Company”) today announced that it has entered into an agreement to
resolve the previously disclosed securities class action litigation
pending in the United States District Court for the District of
Maryland (In re Emergent BioSolutions Inc. Security Litigation, No.
8:21-cv-00955-DLB). This lawsuit was originally filed in 2021.
Under the terms of the proposed settlement, Emergent will pay
$40 million, which will be substantially paid from insurance
proceeds, to settle claims brought on behalf of stockholders who
purchased Emergent’s common stock between March 10, 2020, and
November 4, 2021. The proposed settlement, which is subject to
court approval, includes no admission of liability or wrongdoing by
Emergent or any current or former Emergent officers, directors or
employees and will resolve all claims against the Company and other
defendants in this matter.
“While Emergent believes that the legacy securities class action
was without merit, we are pleased to have reached this agreement,”
said Joe Papa, president and chief executive officer of Emergent.
“Today’s announcement is a major step toward allowing us to move
past this matter so we can continue focusing on our multiyear plan
to turnaround and transform the business.”
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25
years, we’ve been at work defending people from things we hope will
never happen—so we are prepared just in case they ever do. We
provide solutions for complex and urgent public health threats
through a portfolio of vaccines and therapeutics that we develop
and manufacture for governments and consumers. We also offer a
range of integrated contract development and manufacturing services
for pharmaceutical and biotechnology customers. To learn more about
how we plan to protect or enhance 1 billion lives by 2030, visit
our website and follow us
on LinkedIn, X, Instagram, Apple
Podcasts and Spotify.
Safe Harbor Statement
This communication includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical fact,
including statements regarding the ability to obtain final court
approval of the proposed settlement, the ability to satisfy the
conditions of the proposed settlement, and the source of funds to
be used to resolve these matters, are forward-looking statements.
We generally identify forward-looking statements by using words
like “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,”
“position,” “possible,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would,” and similar expressions or
variations thereof, or the negative thereof, but these terms are
not the exclusive means of identifying such statements.
Forward-looking statements are based on our current intentions,
beliefs and expectations regarding future events based on
information that is currently available. We cannot guarantee that
any forward-looking statement will be accurate. Readers should
realize that if underlying assumptions prove inaccurate or unknown
risks or uncertainties materialize, actual results could differ
materially from our expectations. Readers are, therefore, cautioned
not to place undue reliance on any forward-looking statements. Any
forward-looking statement speaks only as of the date of this
communication and, except as required by law, we do not undertake
any obligation to update any forward-looking statement to reflect
new information, events or circumstances.
There are a number of important factors that could cause our
actual results to differ materially from those indicated by any
forward-looking statements. Readers should consider this cautionary
statement, as well as the risk factors and other disclosures
included in our periodic reports filed with the Securities and
Exchange Commission, when evaluating our forward-looking
statements.
Investor Contact:Richard S. LindahlExecutive
Vice President, CFOlindahlr@ebsi.com
Media Contact:Assal HellmerVice President,
Communicationsmediarelations@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Dec 2023 to Dec 2024